TTRX

Turn Therapeutics Inc. (TTRX) - Q3 2025 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended September 30, 2025. Turn Therapeutics Inc. is a pharmaceutical and medical device development company focused on its proprietary PermaFusion® platform. The company changed its name from Global Health Solutions, Inc. in September 2025. Key business activities include the development of drug candidates for dermatological diseases (eczema, onychomycosis) and FDA-cleared medical devices. The company completed a direct listing on The Nasdaq Global Market on October 8, 2025, subsequent to the reporting period.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: General and administrative (G&A) expenses increased significantly, rising from $519,710 in Q3 2024 to $1,754,856 in Q3 2025. This increase is primarily attributed to accruals for legal, advisory, and professional fees related to the company's direct listing on Nasdaq.
• Net Loss: The net loss for the nine months ended September 30, 2025, was $3.47 million, compared to $1.45 million in the same period in 2024. The widening loss is driven by increased G&A costs and continued R&D investments.
• Liquidity: Cash and cash equivalents increased from $872,599 at December 31, 2024, to $3,106,157 at September 30, 2025. This improvement was driven by net proceeds of approximately $3.74 million from equity issuances (Regulation Crowdfunding, Regulation A+, and Regulation D offerings) during the nine-month period.
• Stock Split: A 2-for-1 forward stock split was effected on September 30, 2025. All share and per-share data in this report have been retroactively adjusted to reflect the split.

Guidance, Outlook, and Risks

• Capital Needs: Management estimates that current cash resources will fund operations into the first quarter of 2026. The company anticipates requiring approximately $18.0 million to $20.0 million to complete planned Phase 3 trials for eczema and onychomycosis, and $1.5 million to $2.5 million for its vaccine program.
• Going Concern: The filing expresses substantial doubt about the company's ability to continue as a going concern for at least 12 months from the issuance date without additional financing.
• Financing Strategy: The company intends to fund future operations through equity/debt financings and a Share Purchase Agreement with GEM Global Yield LLC SCS, which allows for the sale of up to $85.0 million of common stock. An initial draw-down of $3 million was executed in late October 2025.
• Clinical Progress: A Phase 2-equivalent trial for GX-03 (eczema) initiated in July 2025 is progressing with approximately 30% of enrollees completed. The company plans to initiate Phase 3-equivalent trials for onychomycosis in 2026.
• Internal Controls: A material weakness in internal controls over financial reporting (related to stock-based compensation and segregation of duties) identified in 2024 has been remediated as of September 30, 2025.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $3.1 million cash balance against the projected $20M+ capital requirement for clinical trials.
• Dilution Risk: Review the terms of the GEM Share Purchase Agreement ($85M aggregate limit) and the 4% warrant issued to GEM, which could lead to significant shareholder dilution.
• Revenue Recognition: Confirm the status of the $1.44 million deferred revenue from the MiMedx licensing agreement and the timeline for recognition.
• Clinical Milestones: Monitor the completion of the GX-03 eczema trial and the initiation of the onychomycosis Phase 3-equivalent trial.
• Post-Listing Performance: Assess the trading volume and price stability of TTRX following its October 8, 2025, direct listing on Nasdaq.